Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879605 | 0.77 | ESR1 (0.41) | HPGDKMT2AMEN1RIPK1 | |
| SCHEMBL6474754 | 0.73 | HPGD (0.68) | LMNAHPGDMAPK1 | |
| SCHEMBL20618549 | 0.73 | ACHE (0.55) | LMNAHPGDCHRM1CHRM4CHRM5 | |
| SCHEMBL422791 | 0.69 | ESR1 (0.45) | MAPK1KMT2ARIPK1PKM | |
| SCHEMBL784996 | 0.69 | TRIM24 (0.39) | POLBLMNAHPGDKMT2APKM | |
| SCHEMBL9136294 | 0.68 | CYP2B6 (0.42) | CYP2C9POLBLMNACHRM1KMT2A | |
| SCHEMBL30032441 | 0.68 | MLYCD (0.48) | POLBLMNAHPGDCHRM1CHRM4 | |
| SCHEMBL2295165 | 0.68 | LMNA (0.74) | POLBLMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL467515 | 0.67 | MEN1 (0.59) | CYP2C9SMN1; SMN2KMT2AMEN1 | |
| Ethylene SCHEMBL8379309 | 0.67 | ESR1 (0.42) | MAPK1KMT2ARIPK1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124600-A1 | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| US-20090124600-A1 | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| EP-1874318-A2 | N-ALKYL-AZACYCLOALKYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113471-A2 | N-ALKYL-AZACYCLOALKYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006113471-A2 | N-ALKYL-AZACYCLOALKYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124600-A1 | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists | GRIN2B, GRIN2A, GRIN1 | CYP2C9 919/4885GRIA2 15/4885POLB 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.